Company intelligence / Profile preview
Bicara Therapeutics
Boston, Massachusetts, United Statesbicara.com ↗
- Ownership
- Public · BCAX
- Employees
- ~55
- Development stage
- Other
01
Overview
Bicara’s lead asset, ficerafusp alfa, has shown encouraging interim Phase 1/1b data demonstrating durable and clinically meaningful anti-tumor activity in combination with pembrolizumab. The company has initiated a pivotal global Phase 2/3 trial in first-line recurrent/metastatic HNSCC. Additional expansion cohorts are ongoing or planned across multiple solid tumor indications
- Therapeutic areas
- Oncology
- Modalities
- Bifunctional antibodies (biologics engineered to combine tumor-targeting and tumor microenvironment modulation)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Pembrolizumab supplied by Merck & Co. for combination trials; no major disclosed pharma partnerships as of May 2025.
04
Financials
- Market cap
- $542M
- Total revenue
- $0
- Enterprise value
- $45.9M
Beyond the preview
Go deeper on Bicara Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bicara Therapeutics.